Pharmaceutical

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast cancers.

Apr 6, 2025 - 06:00
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast cancers.
Read the original article

Tags:

Previous Article

Uveitis market expected to reach $1.5bn across 7MM by 2033

Next Article

‘Fear and uncertainty’ linger over FDA’s future in wake of Trump admin’s layoffs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Medicare eligibility is tripping up the GOP presidential candidates

Medicare eligibility is tripping up the GOP presidentia...

Nov 9, 2023

Tourmaline shifts focus to developing anti-IL6 antibody following merger

Tourmaline shifts focus to developing anti-IL6 antibody...

Oct 21, 2023

STAT+: Alnylam reports growth in sales of rare disease treatments

STAT+: Alnylam reports growth in sales of rare disease ...

Aug 3, 2023